Acurx Pharmaceuticals (ACXP) Receivables - Other (2026)
Acurx Pharmaceuticals' (ACXP) quarterly Receivables - Other came in at $44971.0 in Q2 2026.
Powered by 
Analysis
Acurx Pharmaceuticals (ACXP) Receivables - Other (2026) Analysis & Trends
Acurx Pharmaceuticals (ACXP) has reported Receivables - Other for 1 consecutive years, with $44971.0 the latest figure, recorded in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn |
| 10 | Acurx Pharmaceuticals | 6.65 Mn | 6.65 Mn | - |